FDA
Edit

FDA

https://www.fda.gov/
Last activity: 18.09.2024
Active
Categories: CosmeticDrugFoodTechHardwareHealthTechHumanMedTechPageProductPublic
Comment Policy

This Facebook Page was created as an informational resource for updates from the U.S. Food and Drug Administration.

Facebook encourages and allows for the submission of written comments. In accordance with the Federal Government’s other social media comment policies, the FDA has instituted the following comment policy:

General Comment Guidelines:

To maintain respectful interaction on this page, we encourage that all comments:
• Stay focused. All viewpoints are welcome, but comments should remain relevant to this Facebook page and the associated website (http://www.fda.gov/).
• Be respectful. Respect others opinions and share your opinions in a respectful way.
• Tell the truth. Spreading misleading or false information is prohibited.
• No spam. Repeated posting of identical or very similar content in a counter-productive manner is prohibited — this includes posts aggressively promoting services or products.

Comment Expectations:

Although we hope that you choose to contribute your comments, to protect your privacy, please do not disclose personally identifiable information about yourself or others. We welcome your comments and request that you respect this informational resource. Also, any comments, posts or links that seek to defame, slander or libel any current or former employees of the FDA will be removed.

We will consider your comments when posting new updates, but we are unable to respond directly to individual inquiries. We are also unable to answer questions about your specific health care situation.

The FDA does not endorse the comments or opinions provided by visitors to this site. Following/being followed also does not imply endorsement.

We retain the discretion to determine which comments violate our comment policy. We also reserve the right to remove and/or not allow comments to get posted. The views expressed within posted comments do not necessarily reflect those of the U.S Food and Drug Administration, or the federal government.

Comment Removal:

Comments could be deleted if they:
• Contain commercial endorsements
• Contain discriminatory, racist, offensive, obscene, inflammatory, unlawful, or otherwise objectionable statements, language or content.
• Violate the spirit of this comment policy.

Records will be kept of all comments that are deleted for the above reasons. We reserve the right to block or delete repeat offenders of this policy.
Likes
740.11K
Followers
479.84K
Website visits
11.4M /mo.
Mentions
9.84K
Location: United States, Maryland, White Oak
Employees: 10001+
Phone: +1 888-463-6332
Founded date: 1906

Mentions in press and media 9841

DateTitleDescription
18.09.2024Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual CongressBARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, thi...
18.09.2024Система обнаружения апноэ во сне Apple Watch получила одобрение FDAНедавно Управление по контролю за продуктами и лекарствами США опубликовало одобрение на использование функции обнаружения апноэ во сне на часах Apple Watch Series 9, Series 10 и Watch Ultra 2, сообщает TechCrunch. «Зеленый свет» был дан за...
17.09.2024Pairwise: Cultivating the Future of Agriculture with Gene EditingIn the heart of Durham, North Carolina, a revolution is brewing. Pairwise, a technology company at the forefront of gene editing, has just secured $40 million in Series C funding. This latest round, led by Deerfield Management, pushes their...
17.09.2024FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancerFDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer On September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with a...
17.09.2024Pairwise raises $40m series C, forms JV with Corteva to accelerate gene editing on row cropsPairwise, a startup pioneering gene editing in plants, has closed a $40m series C funding round and formed a five-year joint venture collaboration with agtech giant Corteva to advance the tech to increase climate resilience in corn and soy....
17.09.2024Putting the Pieces Together: REMS Logic Model in REMS Design, Implementation, and Evaluation - 11/07/2024On This Page Date: November 7, 2024 Time: 1:00 PM - 2:30 PM ET Visit CDER Small Business and Industry Assistance Page ABOUT THIS EVENT (Hosted by CDER SBIA) This webinar aims to inform stakeholders, particularly those who design, implement ...
17.09.2024FDA Roundup: September 17, 2024For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for...
17.09.2024FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancerOn September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epiderma...
16.09.2024CBER-Regulated Products with Supporting DocumentsA None Aptima HIV-1 Quant Dx Assay Hologic, Inc. None Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Barr Labs, Inc. ADAMTS13, recombinant-krhn ADZYNMA Takeda Pharmaceuticals U.S.A., Inc. afamitresgene autoleucel TECELRA Adaptimmune LLC A...
16.09.2024Infusion Pump Administration Set Recall: Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration SetsThis recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product Product N...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In